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Abstract 
Purpose: The standard primary treatment for soft tissue sarcoma (STS) is a wide surgical resection, preceded or 
followed by radiotherapy. Purpose of this retrospective study was to assess the efficacy of perioperative brachytherapy 
(BRT) plus postoperative external beam radiation therapy (EBRT) in patients with intermediate-high risk STS. 
Material and methods: BRT delivered dose was 20 Gy. External beam radiation therapy was delivered with 3D-tech-
nique using multiple beams. The prescribed dose was 46 Gy to the PTV. Neoadjuvant and adjuvant chemotherapy 
(CHT) was used in patients with potentially chemosensitive histological subtypes. The primary aim of the study was 
to analyze overall survival (OS) and local control (LC) in a large patient population treated with surgery, perioperative 
BRT, and adjuvant EBRT ± CHT. Secondary objective was to identify prognostic factors for patients outcome in terms 
of LC, disease-free survival (DFS), and OS. 
Results: From 2000 to 2011, 107 patients presenting 2-3 grade (FNLCC) primary or recurrent STS were treated 
with surgery, perioperative BRT, and adjuvant EBRT ± CHT. Five-year LC and OS were 80.9% and 87.4%, respective-
ly. At univariate analysis, a higher LC was recorded in primary vs. recurrent tumors (p = 0.015), and in lower limb 
tumors vs. other sites (p = 0.027). An improved DFS was recorded in patients with lower limb tumors vs. other sites 
(p = 0.034). 
Conclusions: The combination of BRT and EBRT was able to achieve satisfactory results even in a patients popula-
tion with intermediate-high risk STS. Patients with recurrent or other than lower limb sited tumors show a worse LC. 
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Purpose 
Soft tissue sarcoma (STS) represents 1% of all adult ma-
lignancies and 15% of pediatric ones. In 2016, 12,310 people 
will be diagnosed with STS in USA [1]. 
Postoperative external beam radiation therapy (EBRT) 
is considered a standard treatment option. In fact, post-
operative EBRT reduces local recurrence rate compared 
with surgery alone [2,3]. Furthermore, the use of EBRT 
achieves the same survival as radical surgery, without the 
cost of major functional impairment from amputation or 
extended resection [4]. 
Some of published experiences seems to suggest that 
the use of a boost with brachytherapy (BRT) can further 
improve local control rate achievable with adjuvant EBRT 
[5,6,7,8,9,10,11,12]. 
Unfortunately, there is a little evidence in literature 
on the role of BRT. In fact, most available studies are 
retrospective and analyze limited number of patients 
[8,13,14,15,16,17]. Furthermore, these studies included 
patients with different risk categories (low, intermediate, 
high). Large series on BRT boost in adjuvant setting are 
still necessary to define the optimal treatment schedule 
[18]. Therefore, the purpose of this study was to consec-
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utively and homogeneously analyze a large population 
of patients treated with surgery, followed by adjuvant 
EBRT and BRT boost. 
Material and methods 
Study design 
Medical patients charts, presenting grade 2-3 according 
to FNLCC (French Fédération Nationale des Centres de 
Lutte contre le Cancer) system [19], primary or recurrent 
deep STS of extremities or trunk treated with surgery and 
perioperative BRT followed by adjuvant EBRT ± CHT were 
retrospectively analyzed. Patients receiving unplanned 
surgery were excluded. 
Patients characteristics 
One hundred and seven patients (median age: 54 years; 
range: 13-85), treated from January 2000 to January 2011 for 
high grade primary or recurrent STS were included in this 
retrospective analysis. Patient and tumor characteristics 
are shown in Table 1. Median follow-up was 100 months 
(range: 48-176). 
End points 
The primary end point of the study was to analyze 
overall survival (OS). Secondary end point was to identi-
fy prognostic factors of patients outcome in terms of local 
control (LC), metastasis-free survival (MFS), and disease- 
free survival (DFS). 
Staging 
Biopsy was always requested before surgery. Before 
treatment, all patients underwent chest computed tomog-
raphy (CT), contrast-enhanced magnetic resonance imag-
ing (MRI), CT, and double contrast enhanced ultrasound 
of the affected site. The treatment started after histology 
assessment and staging completion. 
Surgery 
Surgical resection was performed according to the fol-
lowing criteria. The incision was made along the major 
axis of the tumor-bearing anatomical compartment and 
included the biopsy track en bloc. The quality of surgery 
was defined by its worst margins and was classified in 
intralesional, marginal, and wide according to Enneking 
classification [20]. Once the skin fat-flap was prepared, 
the tumor was isolated within the tumor-bearing struc-
ture and removed en bloc with the surrounding soft tis-
sue, covered at every point by at least one centimeter of 
healthy tissue, or less if constituted by an anatomical bar-
rier (fascia or periosteum). 
Brachytherapy 
At the time of surgical excision, the clinical target vol-
ume (CTV) of BRT was defined by surgical, pathological, 
and imaging findings. Surgical clips were placed at the 
margins of the tumor bed, and a minimum margin be-
tween clips and CTV was used. Placement of the cathe-
Table 1. Patients and treatment characteristics 
Parameter n %
Histology
Undifferentiated pleomorphic sarcoma (UPS) 27 25.2
Synovial sarcoma 20 18.7
Myxofibrosarcoma 13 12.1
Liposarcoma 19 17.8
Leiomyosarcoma 11 10.3
Other 17 15.9
Tumor
Primary 44 41.1
Recurrent 63 58.9
Surgical margins
Wide 72 67.3
Marginal 29 27.1
Intralesional 6 5.6
Gender
Male 56 52.3
Female 51 47.7
Age (y)
≤ 54 54 50.5
> 54 53 49.5
Site
Upper limb 34 31.8
Lower limb 64 59.8
Other 9 8.4
pT
T1b 48 44.9
T2b 59 55.1
Grade
2 10 9.4
3 97 90.6
Neoadjuvant chemotherapy
No 89 83.2
Yes 18 16.8
Adjuvant chemotherapy
No 82 76.6
Yes 25 23.4
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ters and hollow needles were inserted through the skin 
and soft tissue parallel or perpendicular to the incision. 
The distance between the wound incision and the catheter 
entry point was 1-2 cm. Needles were replaced with BRT 
catheters with 1-1.5 cm intervals to ensure adequate do-
simetry. Catheters could be opened at one or both ends, 
blind-ended, and terminated with the wound. Once the 
catheters were in situ with the wound closed, an adequate 
space (0.5 cm) between the catheter buttons and the skin 
was ensured for postoperative edema. Dummy ribbons 
as anatomical landmarks and potential source positions 
were inserted before a planning CT (sliced obtained at 
5 mm intervals) performed 1 week after surgical resection. 
Catheters were individually numbered. The ribbon recon-
struction allowed to identify the basal points where the 
dose distribution was calculated. 
Treatment planning was performed using computer- 
based optimization algorithms. Once the dosimetry was 
completed, the prescription dose was delivered to the CTV. 
The treatment time was determined based on pre scribed 
dose and dose rate. In low-dose-rate (LDR) (2001-2003) and 
pulsed-dose-rate (PDR) (2004-2011), the median peripheral 
dose rate, defined as the lowest continuous isodose rate line 
covering the CTV was identified. This was generally 5 mm 
from the plane of the implant. The CTV D60%, D80%, D100%, 
D120%, D140%, D160% (the minimum dose to 60-160%) of the 
CTV were always reported. Once the treatment planning 
was calculated and the dose distribution was evaluated 
and accepted, the catheters were connected to a projection 
sources of Iridium-192 and the dose was delivered through 
the automatic loading of miniaturized sources. 
The delivered dose was 20 Gy at dose-rate of 0.30- 
0.80 Gy/hour, and 0.80 Gy/pulse for LDR and PDR, re-
spectively. The treatment lasted 24-30 hours and 24 hours 
for LDR and PDR, respectively. A hospitalization for 1-2 
day was necessary. Once the treatment was completed, the 
catheters were removed. 
External beam radiation therapy 
Simulation was generally performed 3-4 weeks after 
surgical resection, 2-3 weeks after brachytherapy treat-
ment. Patients were immobilized in supine or prone 
position with different immobilization devices, such as 
vacuum cushions, cradle devices, feetstep (feet support 
cushion), or kneestep (knee support cushions). Plan-
ning CT slices for each patient were obtained at 5-mm 
intervals, including the surgical wound with adequate 
margins. 
Patients underwent a pre-operative MRI-scan, which 
was co-registered, if possible, with the planning CT scan 
for delineation of target volumes and normal tissues in-
cluding the organs at risk (OAR). The CTV was identified 
by planning CT and preoperative MRI, and was defined 
as the tumor and surgical bed, including the scar and the 
drainage site, adding 3 cm longitudinally and 1 cm radi-
ally. These margins were reduced at surfaces of fascia and 
bones, unless invaded. 
CTV was expanded into planning target volume 
(PTV) by adding an isotropic 1-cm margin to account 
for uncertainties setup. Also OAR (bones, joints, testi-
cles, bladder, rectum, intestine for low extremities STS; 
bones and lung for upper extremities STS) were delin-
eated. 3D conformal radiotherapy plans were generat-
ed with the requirement that at least 95% of the PTV 
should receive 95% of the prescribed dose. To prevent 
lymphedema, a “soft tissue strip/corridor” was iden-
tified to avoid irradiation of the extremities entire cir-
cumference. Isodose distributions in three planes (axial, 
sagittal, coronal) and cumulative dose-volume histo-
grams of PTV and OAR were used to guide plan opti-
mization. 
The prescribed dose was 46 Gy to the PTV, delivered 
over 23 daily fractions (2 Gy/fraction). A multiple beams 
technique was used in order to achieve the best PTV cov-
erage, while reducing irradiation of OARs and avoiding 
irradiation of contralateral limb (in case of lower limbs 
STS). All patients were treated with 6-18 MV X-rays from 
linear accelerators equipped with multileaf collimators 
with 1-cm leaf width at the isocenter. To ensure the cor-
rect positioning, patient setup was checked at least on 
a weekly basis by using electronic portal images device. 
Deviations > 5 mm were immediately corrected. Exter-
nal beam radiation therapy started within 90 days after 
surgery. 
Chemotherapy 
Neoadjuvant and adjuvant chemotherapy (CHT) con-
sisted of epirubicin (60 mg/m2/day, short infusion, days 
1-2) and ifosfamide (3 g/m2/day, days 1-2-3) were pre-
scribed to those patients with potentially chemosensitive 
histological subtypes. The number of CHT cycles ranged 
between 3 and 5. In case of neoadjuvant chemotherapy, 
surgery was performed at the end of the last cycle, after 
recovery from hematological toxicity and instrumental re-
staging. External beam radiation therapy was performed 
at the end of adjuvant CHT after the recovery from bone 
marrow toxicity. In the interval periods, prophylactic use 
of granulocyte colony-stimulating factor (G-CSF) was 
recommended. The interval between adjuvant CHT and 
EBRT was assessed case by case, depending on the hema-
tological toxicity manifested by each individual patient. 
Dose modifications 
According to hematological toxicity, the following 
recommendations for dose adjustment were provided. 
Grade 0-1 toxicity did not require CHT dose reductions. If 
grade 2 toxicity was registered, a 25% CHT dose reduction 
was recommended and G-CSF were prescribed. In case of 
grade 3-4 toxicity, CHT was interrupted until recovery of 
toxicity to the grade ≤ 2. External beam radiation therapy 
was interrupted only in case of grade 3-4 toxicity, until 
recovery of toxicity to grade ≤ 2. 
Follow-up 
Patients were evaluated 3 weeks after RT or CHT com-
pletion, every 3 months thereafter for the first 2 years, then 
every 6 months for the first 5 years, and later annually. 
Patients evaluation included history and physical exam-
ination, blood tests of metabolic panel and hematological 
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Table 2. Univariate analysis (5-year results) 
Parameter Nr 
Pts
Local 
control
p Metastases- 
free 
survival
p Disease- 
free 
survival
p Overall 
survival
p
Group
Primary 44 90.9 0.015 63.4 0.123 60.2 0.848 95.2 0.342
Recurrent 63 74.2 74.2 57.6 82.6
Histology
UPS 27 95.8 0.125 62.4 0.284 62.4 0.895 82.9 0.069
Synovial sarcoma 20 85.0 67.8 58.3 82.1
Myxofibrosarcoma 13 68.4 83.9 60.6 100.0
Liposarcoma 19 71.9 81.2 53.8 100.0
Leiomyosarcoma 11 90.9 63.6 63.6 72.7
Other 17 68.4 64.9 55.4 90.9
Margins
Wide 72 86.1 0.075 73.6 0.626 63.3 0.369 91.6 0.259
Marginal 29 70.5 61.0 48.2 77.9
Intralesional 6 66.7 67.7 50.0 83.3
Gender
Male 56 83.0 0.392 71.3 0.755 59.3 0.864 86.7 0.858
Female 51 78.5 68.4 58.0 88.2
Age
≤ 54 54 79.5 0.700 68.1 0.814 56.2 0.800 91.2 0.196
> 54 53 82.7 72.3 62.0 82.8
Site
Upper limb 34 64.7 0.027 61.5 0.370 38.4 0.034 77.9 0.422
Lower limb 64 90.1 75.8 71.0 89.8
Trunk 9 74.1 55.6 41.7 100.0
Grade
2 10 67.5 0.203 88.9 0.202 56.3 0.980 83.3 0.794
3 97 82.2 67.9 58.7 87.6
pT
T1b 48 76.9 0.420 75.8 0.115 62.2 0.283 81.6 0.195
T2b 59 84.3 65.3 56.0 92.4
Stage
II 49 75.3 0.196 76.2 0.092 60.9 0.421 81.7 0.201
III 58 85.8 64.8 57.0 92.3
CT Pre
No 89 81.5 0.361 69.7 0.960 58.2 0.656 88.6 0.245
Yes 18 76.9 70.5 60.6 81.0
CT Post
No 82 78.8 0.389 74.3 0.147 60.7 0.575 89.4 0.244
Yes 25 87.8 54.9 52.1 81.3
CT – chemotherapy, UPS – undifferentiated pleomorphic sarcoma 
profile, ECOG status, and toxicity assessment. Chest CT 
and a contrast-enhanced MRI, CT, and double contrast 
enhanced ultrasound of the affected site were performed 
3 months after the treatment and every 6 months for the 
first 5 years. 
Statistical analysis 
Statistical analysis was performed using SYSTAT, ver-
sion 11.0 (SPSS, Chicago, IL). Univariate analyses were per-
formed to evaluate individual risk factors. For each variables 
Journal of Contemporary Brachytherapy (2017/volume 9/number 3)
Adjuvant brachytherapy in soft tissue sarcomas 5
category, LC, MFS, DFS, and OS were estimated according 
to the Kaplan-Meier method, and the log-rank test was used 
to compare survival curves. Multivariable analysis was not 
conducted when investigating local control or death due 
to the limited number of events (19 and 13, respectively). 
For disease-free survival, multivariable analysis were 
not conducted because only one predictor (namely, site), 
reached the statistical significance threshold (p < 0.10) es-
tablished a priori. When studying metastases-free survival, 
there was no predictor reaching the statistical threshold. 
The differences were considered statistically signifi-
cant if the p-value was < 0.05. 
Results 
Patients outcome 
1-year and 3-year LC were 96.2% and 86.3%, respective-
ly. Overall, 5-year LC was 80.9%: 90.9% for primary STS 
and 74.2% for recurrent tumor. Three-year and 5-year MFS, 
DFS, and OS were 76.9%, 69.4%, 95.1%, and 69.8%, 58.6%, 
87.4%, respectively. Overall, during follow-up, 19 pa tients 
developed local recurrence, 30 patients distant metastases, 
42 patients relapse events, and 13 patients died. 
Univariate analysis 
Table 2 shows the results of the univariate analysis. 
A higher LC rate was recorded in patients treated for pri-
mary sarcomas compared to recurrent tumors. Patients 
with lower limbs STS showed a better 5-year LC compared 
to upper limbs or trunk sarcomas. A trend between LC 
and margin status was also recorded with higher LC rate 
in patients with wide surgical margins. The other analyzed 
parameters did not show a significant correlation or trend 
with LC. Disease-free survival was significantly correlated 
to the disease site: 5-year DFS was 71.0% for lower limbs, 
and 38.4% and 41.7% for upper-limb and trunk tumors, 
respectively (Figure 1). A trend was observed between 
histology and OS (p = 0.069) with myxofibrosarcoma and 
liposarcoma showing a better survival. Leiomyosarcoma 
showed a high LC rate (5-year LC, 90.9%) while showing 
a relatively poor outcome in terms of OS (5-year OS, 72.7%). 
Discussion 
Our study was performed in order to assess the im-
pact of adjuvant EBRT and anticipated BRT boost on LC 
in patients with STS. To the best of our knowledge, it is 
the largest series on adjuvant EBRT plus BRT boost in STS. 
This study has the limitation of a retrospective assess-
ment, variable use of chemotherapy, and absence of data 
on acute and late toxicities. Moreover, patients recruit-
ment took place over a long period of time (10 years). This 
could have reduced the homogeneity in patients man-
agement due to evolution of staging and treatment tech-
niques. Furthermore, data about treatment interruption 
or delay are missing. However, all patients were followed 
by the same team of radiologists, radiation oncologists, 
surgeons, and medical oncologists and all patients under-
went the same type of combined treatment (BRT + EBRT) 
with uniform doses. 
We should admit that preoperative RT is able to re-
duce late morbidity compared to postoperative RT [21], 
and that BRT has very limited role in STS in the present 
intensity modulated RT era. However, being postoper-
ative RT still used in several centers, we presented our 
large series of patients with prolonged follow-up. In our 
study, as expected, a correlation was observed between 
tumor type (primary vs. recurrent) and LC (90.9% vs. 
74.2%; p = 0.015), without a significant impact on MFS, 
DFS, and OS. The same significant correlation between 
tumor type and LC was found in other publications. Pet-
era et al. [12] examined the results of 34 patients with STS, 
treated between 1998 and 2007 with HDR-BRT (mean 
dose 24 Gy; 15-30 Gy) and EBRT (40-50 Gy), showing 
that LC was 100% in primary tumors and 64% in recur-
rent lesions (p = 0.004). They observed a tendency toward 
more local recurrences in patients with a close/positive 
margin than in patients with a negative margin. Also in 
our study, a statistical trend was found with 5-year LC of 
86.1%, 70.5%, and 66.7% in patients with wide, marginal, 
and intralesional margins, respectively. 
Another significant correlation recorded in our anal-
ysis was between tumor site (lower limb vs. upper limb 
and trunk), and LC and DFS. The worse results recorded 
in upper limb STS may depend on the greater difficulty of 
radical surgery in this dimensionally smaller and richer 
of neurovascular bundles area. 
Table 3 shows the results of the comparison between 
other studies [7,12,13,14,18,22] and our results. Local con-
trol and OS were similar to that recorded in other centers 
despite inclusion of intermediate-high grade (HG) STS 
only. On the contrary, in other published studies, the an-
alyzed populations also included low grade (LG) STS, 
generally showing a better prognosis [7,12,13,14,18,22]. 
The favorable impact of adjuvant radiation therapy on 
LC compared to surgery alone has been shown in several 
studies [7,12,13,14,18,22]. However, it is more difficult to 
Fig. 1. Actuarial disease-free survival correlated to the dis-
ease site
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Table 3. Literature results
Authors
(reference)
Center Median 
follow- 
up
Inclusion 
criteria
No. of 
pa-
tients
EBRT
dose (Gy)
BRT
dose (Gy)
Chemo-
therapy
5-year local 
control
5-year 
overall 
survival
Petera et al., 
2010 [12]
University 
Hospital 
Hradek 
Kralovè, 
Czech  
Republic 
38.4 
(3.6-114)
Primary (17) + 
recurrent (28);
Low risk (20);
Intermediate/ 
high risk (25) 
45 40-50 HDR (30-54; 
median: 40)
in 11 pts.
HDR (15-30; 
median: 24)
in 34 pts.
+/–
74%
70%
Martinez- 
Monge et al., 
2005 [14]
University  
of Navarra, 
Pamplona, 
Spain
23.2 
(2.8-48)
Primary (24) + 
recurrent (1); 
Low risk (9); 
Intermediate/ 
high risk (16) 
25 45 HDR 16-32 +/– 4-year: 
100% local 
80.5% 
regional 
4-year: 
78.2%
Itami et al. 
2010 [13]
National 
Cancer Central 
Hospital, 
Tokyo, Japan
49.7 Primary (12) + 
recurrent (14);
Margins +/–; 
Low risk (2); 
Intermediate/ 
high risk (24) 
26 – HDR 36 +/– 78.2% 
(43.8% recur-
rent 
+ pos. mar-
gins; 
93.3% prim-
itive, 
neg. mar-
gins)
75.6% 
Lazzaro  
et al., 2005 
[7]
IEO, Milano, 
Italy
34 
(12-56)
Primary (32) + 
recurrent (10); 
Low risk (7) +  
intermediate/ 
high risk (35)
42 50  
(40-66) 
in 24 pts
PDR (45-60; 
median: 45) 
in 18 pts. 
PDR (10-29; 
median: 15)
in 24 pts.
+/– 3-year: 89% 3-year: 
83.9%
Andrews  
et al., 2004 
[18]
Fox Chase 
Cancer Center, 
Philadelphia,
USA
62 Low risk (24);
Intermediate/ 
high risk (48);
Unknown (14)
86 50 (40-70)
in 25 pts
59 (50-74)
in 61 pts
LDR (10-20;
median: 16)
in 25 pts.
+/– 90%
83%
82%
72%
San Miguel
et al., 2011 
[22]
Clınica  
Universidad 
de Navarra, 
Spain
49.3 
(5.9-
107)
Primary (50) + 
recurrent (10); 
Low risk (16);  
Intermediate/ 
high risk (44) 
60 45 HDR (16-24) +/– 9-year: 
77.4%
9-year: 
61.5%
Present 
series 
Bologna, 
University, 
Italy 
100 
(48-176)
Primary (44) + 
recurrent (63); 
Intermediate/ 
high risk (107) 
107 46 LDR/PDR 
(20)
+/– 80.9% 87.4%
EBRT – external beam radiation therapy, BRT – brachytherapy, HDR – high-dose-rate, LDR – low-dose-rate, PDR – pulsed-dose rate 
define the role of BRT boost. In fact, only Andrews and 
colleagues [18] analyzed the difference in terms of LC and 
OS between patients treated with perioperative BRT fol-
lowed by EBRT or EBRT alone, and reported an improved 
LC and OS in patients receiving a combined treatment. We 
can observe that several studies reporting on surgery plus 
postoperative EBRT recorded 5-year LC rates (75.5-87.0%) 
similar to our series, where BRT boost was used (80.9%). 
Nevertheless, we should stress again that some of these 
studies included even patients with low-grade disease 
[3,23,24,25,26,27]. Furthermore, two of these trials involved 
only patients with primary tumors [3,24]. 
Conclusions 
In conclusion, the results of this analysis show that 
a combination of BRT and EBRT is able to produce high 
LC and OS rates even in a patients population with inter-
mediate-high risk STS. Therefore, this type of treatment 
could be proposed in patients with the same disease char-
acteristics in combination with CHT in tumors with che-
mosensitive tumors. 
Prospective studies on the use of BRT/EBRT with 
uniform radiation doses and large patient population in 
the adjuvant setting of STS are still needed to define the 
optimal treatment schedule. Particularly, based on our 
Journal of Contemporary Brachytherapy (2017/volume 9/number 3)
Adjuvant brachytherapy in soft tissue sarcomas 7
results, treatment intensification should be tested in pa-
tients with unfavorable prognostic factors (recurrent tu-
mors and other than lower limb sites). 
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